Scrip
Catalyst continues with anti-addiction drug despite Phase II failure
06 October 2009
Asher Mullard
Please Login to read the full article.
06 October 2009
Asher Mullard
Catalyst Pharmaceutical Partners will continue developing its CPP-109 (vigabatrin) anti-addiction drug after reporting that a recent Phase II failure in cocaine addicted patients was likely due to unexpectedly low compliance.
Post hoc analysis of the trial, along with data from a proof-of-concept...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Catalyst halts patient enrolment to save cash
- Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial
- New US labelling for Erbitux and Vectibix recommends against their use for large subset of colorectal cancer patients
- Hopes high for Provenge to become first US-approved therapeutic cancer vaccine
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
